Physician

Vipin Ramprasad Lohiya, M.D.

According to 2025 Medicare claims, Vipin Lohiya, M.D. (NPI: 1013295922) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Fayette, GA. This provider's primary affiliated billing organization is PIEDMONT CANCER INSTITUTE PC (NPI: 1336180637; TIN: 581761689) and primary practice location at 30214-2112.

Lohiya's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 539 traditional Medicare patients, billed 215,089 HCPCS/CPT codes, and received $4,359,140 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 4,026 prescription claims across 463 beneficiaries totaling $10,122,410 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 22 claims. Open Payments data shows 64 records totaling $292,184. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,734 to $4,359,140. Similarly, Part D prescription costs have moved sharply higher in recent years, from $908 to $10,122,410. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	21	34	$2,734
2016	42	63	$3,849
2017	119	15,619	$130,300
2018	382	119,949	$1,198,638
2019	517	130,050	$1,981,137
2020	461	165,892	$2,552,596
2021	507	209,816	$3,518,104
2022	496	205,131	$3,929,023
2023	549	251,946	$4,950,627
2024	539	215,089	$4,359,140

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	11	13	$908
2016	11	18	$2,043
2017	50	153	$63,196
2018	165	1,050	$343,308
2019	227	1,626	$1,129,207
2020	268	2,146	$2,556,841
2021	345	2,716	$4,885,678
2022	371	2,984	$6,959,733
2023	462	3,596	$7,753,605
2024	463	4,026	$10,122,410

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	39	$3,969
2020	N/R	22	$1,274
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	82	525	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	183	620	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	233	323	$60
96372	Injection of drug or substance under skin or into muscle	124	510	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	395	1,299	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	160	4,298	$2,513,177
Verzenio	Abemaciclib	108	3,026	$1,633,182
Pomalyst	Pomalidomide	41	1,148	$940,061
Venclexta	Venetoclax	48	1,402	$552,006
Imbruvica	Ibrutinib	38	1,114	$458,314

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$1,450	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$290,734	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vipin Ramprasad Lohiya, M.D.?

Tedicare shows public-source Medicare data for Vipin Ramprasad Lohiya, M.D. (NPI 1013295922), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vipin Ramprasad Lohiya, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vipin Ramprasad Lohiya, M.D.?

Vipin Ramprasad Lohiya, M.D. is linked to PIEDMONT CANCER INSTITUTE PC (billing NPI 1336180637) in the available physician profile data.

Does Vipin Ramprasad Lohiya, M.D. have Open Payments data?

Vipin Ramprasad Lohiya, M.D. has 64 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.